EPS for Arcadia Biosciences, Inc. (RKDA) Expected At $-2.00

March 19, 2018 - By Maria Brooks

 EPS for Arcadia Biosciences, Inc. (RKDA) Expected At $ 2.00

Analysts expect Arcadia Biosciences, Inc. (NASDAQ:RKDA) to report $-2.00 EPS on March, 20 after the close.They anticipate $0.60 EPS change or 23.08 % from last quarter’s $-2.6 EPS. After having $-2.20 EPS previously, Arcadia Biosciences, Inc.’s analysts see -9.09 % EPS growth. The stock decreased 1.37% or $0.58 during the last trading session, reaching $41.91. About 1.23 million shares traded or 147.27% up from the average. Arcadia Biosciences, Inc. (NASDAQ:RKDA) has declined 43.32% since March 19, 2017 and is downtrending. It has underperformed by 60.02% the S&P500.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Ratings Coverage

Among 2 analysts covering Arcadia Biosciences (NASDAQ:RKDA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Arcadia Biosciences had 2 analyst reports since May 12, 2017 according to SRatingsIntel. As per Friday, July 21, the company rating was maintained by Piper Jaffray. PiperJaffray downgraded the shares of RKDA in report on Friday, May 12 to “Neutral” rating.

Arcadia Biosciences, Inc., an agricultural biotechnology trait company, develops traits that enhance food, feed, and fiber crops worldwide. The company has market cap of $89.44 million. The firm offers a suite of agricultural yield traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, herbicide tolerance, and heat tolerance traits, as well as yield and agronomic trait stacks primarily for food crops, such as corn, rice, wheat, and soybean. It currently has negative earnings. It also provides agricultural product quality traits comprising gamma linolenic acid safflower oil to manufacturers of nutritional supplements, medical foods, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: